Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to $365000.0.

  • Neurogene's Change in Accured Expenses fell 8618.47% to $365000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$409000.0, marking a year-over-year increase of 9281.45%. This contributed to the annual value of -$2.8 million for FY2024, which is 2241.19% up from last year.
  • According to the latest figures from Q3 2025, Neurogene's Change in Accured Expenses is $365000.0, which was down 8618.47% from $2.2 million recorded in Q2 2025.
  • Neurogene's 5-year Change in Accured Expenses high stood at $2.6 million for Q3 2024, and its period low was -$4.9 million during Q1 2024.
  • Over the past 3 years, Neurogene's median Change in Accured Expenses value was $207000.0 (recorded in 2024), while the average stood at -$546636.4.
  • In the last 5 years, Neurogene's Change in Accured Expenses plummeted by 9963.18% in 2024 and then surged by 94927.54% in 2025.
  • Neurogene's Change in Accured Expenses (Quarter) stood at -$3.7 million in 2023, then soared by 79.71% to -$743000.0 in 2024, then soared by 149.13% to $365000.0 in 2025.
  • Its last three reported values are $365000.0 in Q3 2025, $2.2 million for Q2 2025, and -$2.2 million during Q1 2025.